Inflammatory Bowel Diseases Center, Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, 600 South Euclid Avenue, Campus Box 8124 Saint Louis, MO 63110, USA.
Inflammatory Bowel Diseases Center, Division of Gastroenterology, Department of Medicine, University of California San Diego, 9500 Gilman Drive, MC 0956, La Jolla, CA 92093, USA.
Gastroenterol Clin North Am. 2017 Sep;46(3):603-626. doi: 10.1016/j.gtc.2017.05.013.
This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials.
本文综述了乌司奴单抗在已发表的随机临床试验和三级医疗中心的开放标签经验中的疗效、安全性数据（包括妊娠期间的安全性数据），以及该药在肿瘤坏死因子（TNF）拮抗剂治疗失败和未失败的患者中的应用。我们提出了一种在中重度克罗恩病中定位乌司奴单抗与其他药物（TNF 拮抗剂、vedolizumab）联合使用的算法。本文还列举了几种特定的白细胞介素-23 抑制剂药物，包括 brazikumab（MEDI2070）、risankizumab、LY3074828、tildrakizumab 和 guselkumab，以及它们临床试验的现状。
